US2015320724A1PendingUtilityA1
Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
Est. expiryDec 10, 2032(~6.4 yrs left)· nominal 20-yr term from priority
Inventors:Hong-Ping GuanJose M. Castro-PerezHarry DavisSamuel E. EngelDouglas G. JohnsSongnian LinStephen F. PrevisThomas P. RoddyLiangsu WangSheng WangYusheng Xiong
A61P 3/10A61K 31/403A61K 31/194A61K 31/4184A61K 31/404A61K 31/397A61K 31/44A61K 31/415A61K 31/435A61K 9/209A61K 45/06
37
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
Claims
exact text as granted — not AI-modified1 . A method of treating diabetes in a mammalian subject which comprises administering to said mammalian subject:
(a) a glucagon receptor antagonist, and (b) a cholesterol absorption inhibitor; wherein the mammalian subject has an LDL cholesterol plasma level of less than 130 mg/dL.
2 . A method of reducing hyperglycemia in a mammalian subject which comprises administering to said mammalian subject:
(a) a glucagon receptor antagonist, and (b) a cholesterol absorption inhibitor; wherein the mammalian subject has an LDL cholesterol plasma level of less than 130 mg/dL.
3 . The method of claim 1 wherein the subject has an LDL cholesterol plasma level of less than 100 mg/dL.
4 . The method of claim 1 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are present in a single dosage form.
5 . The method of claim 4 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are in a bilayer tablet.
6 . The method of claim 1 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are present each in a separate dosage form for simultaneous or sequential administration.
7 . The method of claim 1 for treating type 2 diabetes.
8 . The method of claim 1 the cholesterol absorption inhibitor compound is:
or a pharmaceutically acceptable salt thereof.
9 . The method of claim 1 wherein the glucagon receptor antagonist compound is a compound selected from the following table of compounds:
or a pharmaceutically acceptable salt thereof.
10 - 11 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.